On Demand 2023 Sunday AM General Sessions

This collection covers general sessions from Sunday's program. This includes plenaries, and symposia. The sessions listed below are included in this package:

  • Plenary: The Buzz on Biologics: To Asthma and Beyond
  • Being In The Know With ABAI
  • Coding & Government Relations
  • Community/Academic Allergist Initiative: Community Allergist Partnership* in Education (CAPE)
  • Asthma: The Good, the Bad, and the Ugly
  • Hot Topics and Practical Pearls in Dermatology

Accreditation
The American College of Allergy, Asthma & Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation
The American College of Allergy, Asthma & Immunology (ACAAI) designates this enduring material for a maximum of 8.75 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Target Audience

Medical professionals who treat patients with allergic and/or immunological conditions:

  • Practicing allergist/immunologists
  • Allergy/immunology Fellows-in-Training
  • Physician assistants
  • Nurses and advanced practice nurses
  • Allied health professionals
  • Primary care physicians
  • Other medical professionals

Learning Objectives

Upon completion of this session, participants should be able to:

  • Differentiate currently available biologics for the treatment of asthma and describe possible future use of biologics for asthma.
  • Differentiate currently available biologics for the treatment of atopic dermatitis and chronic spontaneous urticaria and discuss future therapies for these conditions.Evaluate the use of dupilumab for eosinophilic esophagitis and discuss the latest data on various biologics being studied for IgE-mediated food allergies.
  • Describe coding changes and updates relevant to allergy practice.
  • Cite how allergists and professional organizations have stayed involved with specific examples and calls to action for future work.
  • Understand governmental and legislative updates impacting allergists.
  • Define asthma remission and review its prevalence, predictors, pathophysiology, and treatments that could lead to remission.
  • Describe the unmet needs in asthma care, including optimizing treatments based on asthma phenotype, and challenges implementing guideline-based care.
  • Describe the effect of social determinants of health on disparities in asthma care of our most vulnerable patients.
  • Describe why medical education in community practices is an important component of exposing learners to our specialty – the "why/general."
  • Learn best practices toward becoming involved in local institutions’ educational curricula – the "where" and the what (and navigating the Program Letter of Agreement).
  • Identify appropriate learning objectives for a community practice rotation at each level of training – medical student, resident, Fellow-in Training – the "who" (and College resources to help you at each step with patient care, medical knowledge, resources).
  • Understand the direct and indirect benefits of teaching learners – the "why/specific."
  • Identify and understand treatment options for prurigo nodularis.
  • Learn the difference between a phototoxic versus a photoallergic reaction.Identify common plants which cause phytophotodermatitis.
  • Recognize and identify skin conditions that mimic allergic disorders.
  • Appropriately recognize and treat atopic conditions in skin of color.
  • Understand how to choose the appropriate biologic for AD and CSU.
  • Improve knowledge regarding JAK inhibitors for AD.
  • Recognize and understand common reactions and side effects to cosmetic procedures.
  • Cite the ABAI certification requirements and important deadlines.
  • Understand the CAP scoring process.
  • Define the requirements and expectations of an ABAI Ambassador.
Additional information
Disclosure: 

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all individuals in a position to control or influence the content of an activity must disclose all financial relationships with any ineligible company that have occurred within the past 24 months. The ACCME defines a “ineligible company” as companies whose primary business is producing, marketing, selling, re-selling, or distributing health care goods or services, used by or on patients. Examples of such organizations include: 
 
•    Advertising, marketing, or communication firms whose clients are ineligible companies
•    Bio-medical startups that have begun a governmental regulatory approval process
•    Compounding pharmacies that manufacture proprietary compounds
•    Device manufacturers or distributors
•    Diagnostic labs that sell proprietary products
•    Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
•    Manufacturers of health-related wearable products
•    Pharmaceutical companies or distributors
•    Pharmacy benefit managers
•    Reagent manufacturers or sellers
  
The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org. All identified relevant relationships must be mitigated and the educational content thoroughly vetted for fair balance, scientific objectivity, and appropriateness of patient care recommendations. It is required that disclosure of or absence of relevant financial relationships be provided to the learners prior to the start of the activity.
Learners must also be informed when off-label, experimental/investigational uses of drugs or devices are discussed in an educational activity or included in related materials.
Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI. All identified relevant financial relationships have been mitigated.

Course summary
Available credit: 
  • 8.75 AMA PRA Category 1 Credit™
  • 8.75 Attendance
  • 8.75 CBRN
Course opens: 
12/01/2023
Course expires: 
11/30/2026
Part of: 
On Demand ACAAI 2023 Annual Scientific Meeting General Sessions
Rating: 
0

Kristin C. Sokol, MD, FACAAI
John J. Oppenheimer, MD, FACAAI  
Peck Y. Ong, MD, FACAAI  
Brian P. Vickery, MD, FACAAI
Gina Capozzoli
Brianna Wilkins
Jeffrey R. Stokes, MD, FACAAI
J. Allen Meadows, MD, FACAAI  
Steve Dorman, MD, FACAAI  
Gary N. Gross, MD, FACAAI  
Warner W. Carr, MD, FACAAI  
Matt Reiter
J. Wesley Sublett, MD, MPH, FACAAI  
Kathleen R. May, MD, FACAAI  
David A. Kaufman, MD, FACAAI  
David R. Stukus, MD, FACAAI  
Theresa A. Bingemann, MD, FACAAI
Angela Duff Hogan, MD, FACAAI  
Clinton P. Dunn, MD  
Michael S. Blaiss, MD, FACAAI  
Tamara T. Perry, MD
Kelly M. Maples, MD, FACAAI  
Gisoo Ghaffari, MD, FACAAI  
Alexandra Golant, MD  
Marcella R. Aquino, MD, FACAAI  
Ama Alexis, MD, FACAAI  
Karen S. Hsu Blatman, MD  
Andrew Alexis, MD, MPH  
Marc J. Serota, MD, FACAAI

Available Credit

  • 8.75 AMA PRA Category 1 Credit™
  • 8.75 Attendance
  • 8.75 CBRN
Please login or create an account to take this course.